In the latest twist in the ocean of Zantac-related litigation playing out across state courts, drugmakers have notched a key ...

While Astellas’ Veozah was the first neurokinin 3 (NK-3) receptor antagonist approved for menopause, Lynkuet is the first ...

Eight drugmakers agreed to put legal claims stemming from their roles in the U.S. | Viatris, Hikma, Amneal, Apotex, Indivior, ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

According to a pair of recent rulings by the U.K.’s Prescription Medicines Code of Practice Authority (PMCPA), Jazz ...

Nearly 70 years into her history, Barbie is still undergoing regular makeovers. | Nearly 70 years into her history, Barbie is ...

After reporting a 15% sequential decline in Izervay sales for the opening quarter of this year, Astellas has reversed the ...

After years of investment to upgrade its manufacturing capabilities, Pacira BioSciences figures it’s time to retire a facility that has been running for more than a decade. | After years spent ...

A little over a year after celebrating its 30th anniversary in China with a major production upgrade, Novo Nordisk is back ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

Already late with carrying out his administration's prior threats around pharmaceutical tariffs, President Donald Trump has ...

The pharma began its outreach to the HS community well before securing Bimzelx’s approval in the indication. In the spring of ...